Liver Cancer

LiverPhase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
Anus, Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, Stomach, ThyroidAn Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors
LiverA Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaPrincipal Investigator: Raghav Sundar
Colon, Liver, Lung, Phase I, RectumA Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
Esophagus, Liver, Other Digestive Organ, Pancreas, Small Intestine, StomachPhase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) LevelsPrincipal Investigator: Kiran Turaga